Fresenius Overview

  • Year Founded
  • 1912

Year Founded

  • Status
  • Public

  • Employees
  • 179,493

Employees

  • Stock Symbol
  • FRE

Stock Symbol

  • Investments
  • 27

  • Share Price
  • $56.67
  • (As of Thursday Closing)

Fresenius General Information

Description

Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in the dialysis service provider and equipment manufacturer, Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.

Contact Information

Formerly Known As
Dr. E. Fresenius
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Else-Kroner Strasse 1
  • 61352 Bad Homburg
  • Germany
+49 06172
Primary Industry
Holding Companies
Other Industries
Other Devices and Supplies
Medical Supplies
Stock Exchange
FRA
Corporate Office
  • Else-Kroner Strasse 1
  • 61352 Bad Homburg
  • Germany
+49 06172

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fresenius Stock Performance

As of 19-Nov-2026, Fresenius’s stock price is $56.67. Its current market cap is $31.9B with 563M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$56.67 $58.65 $40.94 - $62.45 $31.9B 563M 2.29K $3.18

Fresenius Financials Summary

As of 30-Sep-2026, Fresenius has a trailing 12-month revenue of $27.4B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 40,838,342 46,213,403 31,134,611 44,351,445
Revenue 27,430,318 25,800,884 23,756,398 22,796,083
EBITDA 4,264,021 4,102,558 3,625,031 2,782,016
Net Income 1,799,719 1,425,800 509,669 (642,753)
Total Assets 47,906,602 48,623,347 45,316,906 50,056,928
Total Debt 13,426,776 14,016,727 14,127,845 17,498,480
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Fresenius Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Fresenius‘s full profile, request access.

Request a free trial

Fresenius Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in the dialysis service pr
Holding Companies
Bad Homburg, Germany
179,493 As of 2026

Bad Homburg, Germany
 

Mentor, OH
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Fresenius Competitors (9)

One of Fresenius’s 9 competitors is Fresenius Medical Care, a Corporation company based in Bad Homburg, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fresenius Medical Care Corporation Bad Homburg, Germany
Steris Formerly PE-Backed Mentor, OH
Baxter India Corporation Gurgaon, India
ICU Medical Corporation San Clemente, CA
Becton, Dickinson and Company Corporation Franklin Lakes, NJ
You’re viewing 5 of 9 competitors. Get the full list »

Fresenius Patents

Fresenius Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-102008026769-A1 Body fluid i.e. autologous blood, suction device for use during auto transfusion, has monitoring device for changing suction power of suction device for suction of air from reservoir depending on negative pressure Active 04-Jun-2008
DE-102008026769-B4 Device and method for aspirating body fluids, in particular for autotransfusion of intraoperative or postoperative blood loss Active 04-Jun-2008
DE-102007011332-A1 Device and method for separating a cell suspension, in particular for separating at least one blood component from whole blood Inactive 08-Mar-2007
EP-2121075-A1 Device and method for the separation of a cell suspension, in particular for the isolation of at least one blood component from whole blood Inactive 08-Mar-2007
WO-2008107167-A1 Device and method for the separation of a cell suspension, in particular for the isolation of at least one blood component from whole blood Inactive 08-Mar-2007 A61M1/0209
To view Fresenius’s complete patent history, request access »

Fresenius Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Fresenius Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Fresenius‘s full profile, request access.

Request a free trial

Fresenius Investments & Acquisitions (27)

Fresenius’s most recent deal was a Secondary Transaction - Private with mAbxience for . The deal was made on 01-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
mAbxience 01-Oct-2026 Secondary Transaction - Private Biotechnology
Avelios 06-May-2026 Later Stage VC Enterprise Systems (Healthcare)
mAbxience 01-Aug-2022 Merger/Acquisition Biotechnology
Delaware Institute for Reproductive Medicine 10-Jan-2022 Merger/Acquisition Clinics/Outpatient Services
Eugin 01-Dec-2020 Merger/Acquisition Clinics/Outpatient Services
You’re viewing 5 of 27 investments and acquisitions. Get the full list »

Fresenius ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

14.01 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Services

Subindustry

of 97

Rank

Percentile

To view Fresenius’s complete esg history, request access »

Fresenius Exits (3)

Fresenius’s most recent exit was on 01-Dec-2020 from Eugin. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Eugin 01-Dec-2020 Completed
Nova Lease Solutions 30-Oct-2000 Completed
Hospitalia International 01-Jan-1994 Merger/Acquisition Completed
To view Fresenius’s complete exits history, request access »

Fresenius Affiliates

Subsidiaries (92)

Name Industry Location Year Founded
Fresenius Ventures Bad Homburg vor der Höhe, Germany 2026
Fresenius Digital Solutions Bad Homburg V. D. Hohe, Germany 2023
Helios Global Health Berlin, Germany 2021
Helios Institut Für Arbeitsmedizin München Munich, Germany 2021
Helios Reinigung West Wuppertal, Germany 2019
You’re viewing 5 of 92 affiliates. Get the full list.  »

Fresenius FAQs

  • When was Fresenius founded?

    Fresenius was founded in 1912.

  • Where is Fresenius headquartered?

    Fresenius is headquartered in Bad Homburg, Germany.

  • What is the size of Fresenius?

    Fresenius has 179,493 total employees.

  • What industry is Fresenius in?

    Fresenius’s primary industry is Holding Companies.

  • Is Fresenius a private or public company?

    Fresenius is a Public company.

  • What is Fresenius’s stock symbol?

    The ticker symbol for Fresenius is FRE.

  • What is the current stock price of Fresenius?

    As of 19-Nov-2026 the stock price of Fresenius is $56.67.

  • What is the current market cap of Fresenius?

    The current market capitalization of Fresenius is $31.9B.

  • What is Fresenius’s current revenue?

    The trailing twelve month revenue for Fresenius is $27.4B.

  • Who are Fresenius’s competitors?

    Fresenius Medical Care, Steris, Baxter India, ICU Medical, and Becton, Dickinson and Company are some of the 9 competitors of Fresenius.

  • What is Fresenius’s annual earnings per share (EPS)?

    Fresenius’s EPS for 12 months was $3.18.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process